Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 6.6% in August

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 25,800 shares, an increase of 6.6% from the August 15th total of 24,200 shares. Based on an average daily trading volume, of 56,000 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently bought and sold shares of GNOM. One Capital Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 22.1% in the 2nd quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock valued at $7,102,000 after purchasing an additional 123,339 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at about $590,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Global X Genomics & Biotechnology ETF by 16.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock valued at $4,431,000 after acquiring an additional 53,178 shares during the period. James J. Burns & Company LLC bought a new position in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at about $181,000. Finally, Archford Capital Strategies LLC raised its holdings in Global X Genomics & Biotechnology ETF by 59.1% in the 2nd quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after acquiring an additional 13,703 shares during the period. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ:GNOM traded up $0.12 during mid-day trading on Tuesday, hitting $11.37. The stock had a trading volume of 53,150 shares, compared to its average volume of 60,767. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $12.53. The stock has a market cap of $84.59 million, a price-to-earnings ratio of -4.81 and a beta of 1.03. The company’s 50 day simple moving average is $11.25 and its 200 day simple moving average is $10.90.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.